**MP0250, a VEGF and HGF neutralizing DARPin® molecule shows high anti-tumour efficacy in mouse xenograft and patient-derived tumour models**

**SUPPLEMENTARY MATERIALS**

Table 1: Anti-tumor response in xenograft and syngeneic mouse models

| Model | Type and Site of implantation | % T/C (tumor volume) | p-values versus vehicle | Comparision groups |
|-------|-------------------------------|----------------------|-------------------------|--------------------|
| A673  | xenograft subcutaneous        | MP0250: 35.5% (p = 0.0139) |                          |                    |
|       |                               | Anti-HGF: 89.8% (p = 0.144) | Anti-VEGF: 24.2% (p = 0.027) |                    |
| U87MG | xenograft subcutaneous        | MP0250: 5.3% (p = 0.0144) |                          |                    |
|       |                               | Anti-HGF: 5.2% (p = 0.075) | Anti-VEGF: 34.1% (p = 0.0143) |                    |
| Renca | syngeneic Orthtopic (kidney)  | MP0250 (4 mg/kg): 10.6% (p = 0.0085) | Sorafenib: 83.95% (p = 0.61) |                    |
|       |                               | MP0250 (40 mg/kg): 7.2% (p = 0.0081) |                          |                    |
| KP4   | xenograft subcutaneous        | MP0250: 51.7% (p = 0.0023) | Gemcitabine: 50.5% (p = 0.0006) | MP0250 plus Gemcitabine: 23% (p = < 0.0001) |
| MC38  | syngeneic subcutaneous        | MP0250: 30.6% (p = 0.0001) | Anti-HGF: 78.1% (p = 0.32) | MP0250 vs. Anti-HGF p= 0.021 |
|       |                               | Anti-VEGF: 48.1% (p = 0.056) | RMP1-14: 64.9% (p = 0.048) | MP0250 vs Anti-VEGF p = 0.028 |
|       |                               | MP0250 plus RMP1-14: 18.8% (p = < 0.0001) |                          | MP0250 vs MP0250 plus RMP-1 |

p = 0.053 (tumor volume); p = 0.049 (tumor weight)
| Model   | Tumor entity                  | HGF-expression (Affimetrix) | VEGFA-expression (Affimetrix) | % T/C MP0250 (day) | % T/C SoC (day) | % T/C MP0250 plus SoC |
|---------|-------------------------------|-----------------------------|-------------------------------|-------------------|----------------|---------------------|
| LIXF 658 | Liver Adeno carcinoma         | high                        | High                          | 6.9% (45)         | 14.1% (31)     | n.a.                |
| LIXF 575 | Liver Hepatocellular carcinoma | low                         | High                          | 37.4% (17)        | 49.1% (17)     | n.a.                |
| LXFL 1121| Lung Large cell               | high                        | High                          | 26.2% (34)        | 87.8% (7)      | n.a.                |
| LXFS 650 | Lung (Metastasis Lymph Node) Small cell | moderate | High                          | 88.7% (24)        | 78.2% (7)      | n.a.                |
| RXF 616 | Kidney (Metastasis Lung Hypernephroma) | high | High                          | 56.4% (13)        | 79.1% (9)      | n.a.                |
| RXF 2264 | Kidney                        | high                        | High                          | 8.9% (25)         | 24.0% (25)     | n.a.                |
| GXA 3002 | Stomach (Asian)               | low                         | High                          | 31.7% (26)        | 46.1% (20)     | 16.7% (26)          |
| GXA 3027 | Stomach (Asian)               | low                         | High                          | 22.2% (24)        | 15.8% (24)     | 0% (24)             |

Tumor inhibition for a particular day (T/C in %) was calculated from the ratio of the median RTV values of test versus control groups multiplied by 100%. The table summarizes the efficacy of the individual treatments (% T/C) and the expression of VEGF and HGF as determined by Affymetrix mRNA expression profiling. Expression data were provided by Oncotest/CRL.